1. Home
  2. ENTX vs IMAB Comparison

ENTX vs IMAB Comparison

Compare ENTX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • IMAB
  • Stock Information
  • Founded
  • ENTX 2010
  • IMAB 2014
  • Country
  • ENTX Israel
  • IMAB United States
  • Employees
  • ENTX N/A
  • IMAB N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • IMAB Health Care
  • Exchange
  • ENTX Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • ENTX 90.2M
  • IMAB 87.2M
  • IPO Year
  • ENTX 2018
  • IMAB 2020
  • Fundamental
  • Price
  • ENTX $2.55
  • IMAB $0.99
  • Analyst Decision
  • ENTX Strong Buy
  • IMAB Strong Buy
  • Analyst Count
  • ENTX 1
  • IMAB 3
  • Target Price
  • ENTX $10.00
  • IMAB $8.00
  • AVG Volume (30 Days)
  • ENTX 86.0K
  • IMAB 270.7K
  • Earning Date
  • ENTX 03-07-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • ENTX N/A
  • IMAB N/A
  • EPS Growth
  • ENTX N/A
  • IMAB N/A
  • EPS
  • ENTX N/A
  • IMAB N/A
  • Revenue
  • ENTX $99,000.00
  • IMAB $3,313,984.00
  • Revenue This Year
  • ENTX N/A
  • IMAB N/A
  • Revenue Next Year
  • ENTX N/A
  • IMAB N/A
  • P/E Ratio
  • ENTX N/A
  • IMAB N/A
  • Revenue Growth
  • ENTX 607.14
  • IMAB N/A
  • 52 Week Low
  • ENTX $0.82
  • IMAB $0.84
  • 52 Week High
  • ENTX $3.35
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 61.93
  • IMAB 43.19
  • Support Level
  • ENTX $2.00
  • IMAB $1.03
  • Resistance Level
  • ENTX $2.62
  • IMAB $1.10
  • Average True Range (ATR)
  • ENTX 0.18
  • IMAB 0.06
  • MACD
  • ENTX 0.01
  • IMAB -0.01
  • Stochastic Oscillator
  • ENTX 96.77
  • IMAB 7.58

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: